Skip to Main Content
Contribute Try STAT+ Today

As the winds shift in Washington, here’s something to depend on: Big pharma and health products companies will be the top spenders on lobbying, and the competition isn’t close. Since 1998, they have doled out $3.7 billion to convince, cajole, entice, or strong-arm Congress and federal agencies — more than $1 billion more than any other industry. That doesn’t count campaign contributions, donations to independent pressure groups, and outlays for politicking at the state level.

Since January 2016, the industry has spent about $144 million on federal lobbying, according to data compiled by the Center for Responsive Politics. It can claim a big victory from last year’s passage of the 21st Century Cures Act, which is expected to speed up Food and Drug Administration drug approvals. Given that, by some measures, a single major drug can sometimes cost nearly as much to bring to market as the industry’s entire lobbying expenditures in the past two decades, it’s safe to say that at least with that law the industry got its money’s worth.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.